• Je něco špatně v tomto záznamu ?

Efficacy and Safety of AM-111 in the Treatment of Acute Unilateral Sudden Deafness-A Double-blind, Randomized, Placebo-controlled Phase 3 Study

H. Staecker, G. Jokovic, S. Karpishchenko, A. Kienle-Gogolok, A. Krzyzaniak, CD. Lin, P. Navratil, V. Tzvetkov, N. Wright, T. Meyer,

. 2019 ; 40 (5) : 584-594. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023921

OBJECTIVE: To confirm the efficacy and safety of AM-111 (brimapitide), a cell-penetrating c-Jun N-terminal Kinase (JNK) inhibitor, in patients suffering from severe to profound acute unilateral idiopathic sudden sensorineural hearing loss (ISSNHL). STUDY DESIGN: Prospective, double-blind, randomized, placebo-controlled phase 3 study with follow-up visits on Days 3, 7, 28, and 91. SETTING: Fifty-one European and Asian sites (tertiary referral centers, private ENT practices). PATIENTS: Two hundred fifty-six patients aged 18 to 65 years presenting within 72 hours following ISSNHL onset with mean hearing loss ≥ 40 dB and mean threshold ≥ 60 dB at the 3 worst affected contiguous test frequencies. INTERVENTIONS: Single-dose intratympanic injection of AM-111 (0.4 or 0.8 mg/ml) or placebo; oral prednisolone as reserve therapy if hearing improvement < 10 dB at Day 7. MAIN OUTCOME MEASURES: Hearing improvement to Day 28 was the primary efficacy endpoint; complete hearing recovery, frequency of reserve therapy used, complete tinnitus remission, improvement in word recognition were secondary endpoints. Safety was evaluated by the frequency of clinically relevant hearing deterioration and adverse events. RESULTS: While the primary efficacy endpoint was not met in the overall study population, post-hoc analysis showed a clinically relevant and nominally significant treatment effect for AM-111 0.4 mg/ml in patients with profound ISSNHL. The study drug and the administration procedure were well tolerated. CONCLUSIONS: AM-111 provides effective otoprotection in case of profound ISSNHL. Activation of the JNK stress kinase, AM-111's pharmacologic target, seems to set in only following pronounced acute cochlear injury associated with large hearing threshold shifts.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023921
003      
CZ-PrNML
005      
20201214131715.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MAO.0000000000002229 $2 doi
035    __
$a (PubMed)31083077
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Staecker, Hinrich $u Department of Otolaryngology, University of Kansas Medical Center, Kansas City, Kansas, U.S.A.
245    10
$a Efficacy and Safety of AM-111 in the Treatment of Acute Unilateral Sudden Deafness-A Double-blind, Randomized, Placebo-controlled Phase 3 Study / $c H. Staecker, G. Jokovic, S. Karpishchenko, A. Kienle-Gogolok, A. Krzyzaniak, CD. Lin, P. Navratil, V. Tzvetkov, N. Wright, T. Meyer,
520    9_
$a OBJECTIVE: To confirm the efficacy and safety of AM-111 (brimapitide), a cell-penetrating c-Jun N-terminal Kinase (JNK) inhibitor, in patients suffering from severe to profound acute unilateral idiopathic sudden sensorineural hearing loss (ISSNHL). STUDY DESIGN: Prospective, double-blind, randomized, placebo-controlled phase 3 study with follow-up visits on Days 3, 7, 28, and 91. SETTING: Fifty-one European and Asian sites (tertiary referral centers, private ENT practices). PATIENTS: Two hundred fifty-six patients aged 18 to 65 years presenting within 72 hours following ISSNHL onset with mean hearing loss ≥ 40 dB and mean threshold ≥ 60 dB at the 3 worst affected contiguous test frequencies. INTERVENTIONS: Single-dose intratympanic injection of AM-111 (0.4 or 0.8 mg/ml) or placebo; oral prednisolone as reserve therapy if hearing improvement < 10 dB at Day 7. MAIN OUTCOME MEASURES: Hearing improvement to Day 28 was the primary efficacy endpoint; complete hearing recovery, frequency of reserve therapy used, complete tinnitus remission, improvement in word recognition were secondary endpoints. Safety was evaluated by the frequency of clinically relevant hearing deterioration and adverse events. RESULTS: While the primary efficacy endpoint was not met in the overall study population, post-hoc analysis showed a clinically relevant and nominally significant treatment effect for AM-111 0.4 mg/ml in patients with profound ISSNHL. The study drug and the administration procedure were well tolerated. CONCLUSIONS: AM-111 provides effective otoprotection in case of profound ISSNHL. Activation of the JNK stress kinase, AM-111's pharmacologic target, seems to set in only following pronounced acute cochlear injury associated with large hearing threshold shifts.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a percepční nedoslýchavost $x farmakoterapie $7 D006319
650    _2
$a náhlá nedoslýchavost $x farmakoterapie $7 D003639
650    _2
$a jednostranná nedoslýchavost $x farmakoterapie $7 D046088
650    _2
$a lidé $7 D006801
650    _2
$a intratympanická injekce $7 D000069555
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a peptidy $x terapeutické užití $7 D010455
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jokovic, Galina $u ENT Hospital "Dr Dragiša MIšović-Dedinje", Belgrade, Serbia.
700    1_
$a Karpishchenko, Sergey $u ENT Department, Pavlov First Saint Petersburg State Medical University, St Petersburg, Russia.
700    1_
$a Kienle-Gogolok, Andrea $u Private ENT practice, Bad Schönborn, Germany.
700    1_
$a Krzyzaniak, Andrzej $u Department of ENT, 10th Military Hospital, Bydgoszcz, Poland.
700    1_
$a Lin, Chia-Der $u Department of Otolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung, Taiwan.
700    1_
$a Navratil, Pavel $u Private ENT practice, Olomouc, Czech Republic.
700    1_
$a Tzvetkov, Ventzislav $u Department of Otolaryngology, Military Medical Academy, Sofia, Bulgaria.
700    1_
$a Wright, Nida $u Department of Otolaryngology, Thammasat University Hospital, Pathum Thani, Thailand.
700    1_
$a Meyer, Thomas $u Auris Medical AG, Basel, Switzerland.
773    0_
$w MED00006516 $t Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology $x 1537-4505 $g Roč. 40, č. 5 (2019), s. 584-594
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31083077 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131713 $b ABA008
999    __
$a ok $b bmc $g 1596240 $s 1114597
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 40 $c 5 $d 584-594 $e - $i 1537-4505 $m Otology & neurotology $n Otol Neurotol $x MED00006516
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace